Skip to main content

Khedezla FDA Approval History

FDA Approved: Yes (First approved July 10, 2013)
Brand name: Khedezla
Generic name: desvenlafaxine
Dosage form: Extended-Release Tablets
Company: Osmotica Pharmaceutical Corp.
Treatment for: Depression

Khedezla (desvenlafaxine) is a serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for the treatment of major depressive disorder.

Development timeline for Khedezla

Jul 11, 2013Approval FDA Approves Khedezla for Major Depressive Disorder

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.